ONCAlert | Upfront Therapy for mRCC
Videos  >  

Combining Immunotherapy and Chemotherapy in Patients With SCLC

Julie R. Brahmer, MD
Published Online:7:49 PM, Mon March 11, 2019

Julie R. Brahmer, MD, co-director of the Upper Aerodigestive Department in the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins Medicine, discusses data for atezolizumab (Tecentriq) plus carboplatin/etoposide versus carboplatin/etoposide alone in patients with small cell lung cancer (SCLC) in the IMpower133 trial.

Brahmer says these data showed that the addition of the immunotherapy improved progression-free survival in these patients. However, it did not improve the response rate.

Atezolizumab clearly maintained the response for longer periods of time compared to the chemotherapy, Brahmer says. This can help in improving overall survival. Moving forward, she says other trials will show whether or not these data remain consistent when combining the PD-1/PD-L1 inhibitors with chemotherapy.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.